Dr. Caggiano is broad-based therapeutic development executive with experience across a range of disease indications, including neurological disorders. Prior to joining Cognition Therapeutics, Dr. Caggiano was acting president and chief medical officer of Constant Pharmaceuticals and Aeromics, Inc., clinical-stage companies respectively developing candidates for central nervous system disorders and cerebral edema following ischemic stroke. Earlier, as senior vice president of research and development at Acorda Therapeutics, he oversaw a staff managing clinical and preclinical research and development programs in multiple sclerosis, spinal cord injury and other neurological disorders.
Location
New York, United States
Links
This person is not in any offices